Threshold dose for peanut: Risk characterization based upon diagnostic oral challenge of a series of 286 peanut-allergic individuals

摘要: Clinical records of 286 consecutive patients reacting positively with objective symptoms to double-blind, placebo-controlled oral peanut challenges at University Hospital, Nancy, France were examined for individual No Observed Adverse Effect Levels (NOAELs) and Lowest (LOAELs). After fitting a log-normal probability distribution model, the ED10 ED05 14.4 7.3 mg (expressed as whole peanut), respectively, 95% lower confidence intervals 10.7 5.2 mg, respectively. Compared results from previous study where was based upon thresholds gleaned 12 publications, statistically significant difference observed between ED50’s, but not ED10’s two curves. The Nancy patient group contains more sensitive subjects than published literature thus contributing differences. Minimum eliciting dose-distributions histories severe reactions (grade 4 or 5; 40 subjects) did differ significantly those less (grades 1–3; 123 subjects). These data this modeling approach could be used establish population peanut-allergic consumers thereby provide sound basis allergen control measures in food industry.